A Clinical Study to Map the HLA Genomic Region in the Greek Population

ConditionsHealthy Respiratory Disease Chronic Renal Failure Cardiovascular Diseases Metabolic Disease Psychiatric Disorder Neurologic Disorder Gastrointestinal Diseases Haematologic Disease Rheumatologic Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAthens LifeTech Park

About this trial

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

Eligibility criteria

Qualifiers

possess a Greek social security number and are visiting hospitals/clinics, and/or other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,

are willing and able to provide written informed consent to participate in the study according to the study protocol.

Disqualifiers

Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).

bone marrow transplant

stem cell transplant

blood transfusion less than two weeks prior to buccal swab sample collection

Trial design

Treatments tested in this trial

Not listed

Trial groups

12,000 Participants

are grouped into 1 trial group

Locations

2nd Propaedeutic Department of Internal Medicine, Attikon University General Hospital12462, ChaïdáriAttica, Greece

2nd Department of Neurology, AHEPA University Hospital54636, ThessalonikiThessaloniki, Greece

Department of Respiratory Medicine, University General Hospital of Alexandroupolis68100, AlexandroupoliThrace, Greece

Department of Infectious Diseases, 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis68100, Alexandroupoli Greece

Sponsors and collaborators

Athens LifeTech Park

Lead sponsor

Galatea.Bio

Collaborator

Source ClinicalTrials.gov